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ABSTRACT: As the number of diagnostic and therapeutic applications
utilizing gold nanoparticles (AuNPs) increases, so does the need for AuNPs
that are stable in vivo, biocompatible, and suitable for bioconjugation. We
investigated a strategy for AuNP stabilization that uses methoxypoly-
ethylene glycol-graf t-poly(L-lysine) copolymer (MPEG-gPLL) bearing free
amino groups as a stabilizing molecule. MPEG-gPLL injected into water
solutions of HAuCl4 with or without trisodium citrate resulted in spherical
(Zav = 36 nm), monodisperse (PDI = 0.27), weakly positively charged
nanoparticles (AuNP3) with electron-dense cores (diameter: 10.4 ± 2.5
nm) and surface amino groups that were amenable to covalent modiﬁcation.
The AuNP3 were stable against aggregation in the presence of phosphate
and serum proteins and remained dispersed after their uptake into
endosomes. MPEG-gPLL-stabilized AuNP3 exhibited high uptake and very
low toxicity in human endothelial cells, but showed a high dose-dependent
toxicity in epithelioid cancer cells. Highly stable radioactive labeling of AuNP3 with 99mTc allowed imaging of AuNP3
biodistribution and revealed dose-dependent long circulation in the blood. The minor fraction of AuGNP3 was found in major
organs and at sites of experimentally induced inﬂammation. Gold analysis showed evidence of a partial degradation of the MPEG-
gPLL layer in AuNP3 particles accumulated in major organs. Radiofrequency-mediated heating of AuNP3 solutions showed that
AuNP3 exhibited heating behavior consistent with 10 nm core nanoparticles. We conclude that PEG-pPLL coating of AuNPs
confers “stealth” properties that enable these particles to exist in vivo in a nonaggregating, biocompatible state making them
suitable for potential use in biomedical applications such as noninvasive radiofrequency cancer therapy.
■ INTRODUCTION
The continuous eﬀort toward AuNP surface modiﬁcation has
demonstrated that the addition of a protective layer to the
surface of nanoparticles drastically improves their stability in
vivo, while maintaining a small particle size. The protection is
usually accomplished by adsorbing and/or chemically orienting
polymers,1−3 thereby generating a layer that becomes sterically
and chemically protective due to a lowering of the eﬀective
surface energy of the colloidal gold surface. Consequently,
surface protection of AuNPs prevents particle aggregation in
biological ﬂuids.4,5
There are numerous strategies that utilize a combination of
reducing/gold colloid capping polymers6 for the formulation of
surface-coated AuNPs. Short di- to tetra-ethylene oxide long
PEG-thiols were ﬁrst suggested for stabilizing AuNPs1,6
analogous to alkanethiols that are commonly used in stabilizing
gold nanocrystals during the synthesis of AuNPs in organic
solvent/water systems.7 Short, low molecular weight PEGs do
not bind or activate complement (unless a terminal hydroxyl is
exposed on PEG chains8,9). However, longer PEG-based
mono-10 or dithiols11 were shown to be more convenient for
AuNP stabilization and functionalization of citrate-reduced
AuNPs and enabled in vivo testing of PEG-coated AuNPs.10,12
These results taken together suggest that an ideal compound
for surface coating of AuNPs would have denser PEG-based
polymers that were devoid of complement activating activity.
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Such surface-stabilized AuNPs are being increasingly
recognized as ideally suited for a number of diagnostic and
therapeutic (theranostic) biomedical applications.13,14 For
example, tumors that accumulate AuNPs can be ablated when
the AuNPs are heated by radiofrequency (RF) electric
ﬁelds15,16 or near-infrared photons17 so as to produce
hyperthermic cytotoxicity in surrounding cells. In addition,
the absorption of 100−200 kV photons by AuNPs results in a
potentiation of ionizing radiation, suggesting that AuNPs may
be useful as radiotherapy enhancing agents in cancer treat-
ment.18,19 In contrast, nonstabilized AuNPs were shown to be
non-bioinert,20 with mild-to-severe nephrotoxicity being
described in several animal species.21 Thus, the development
of biologically safe and eﬀective coating and delivery strategies
for AuNPs will be key in bringing this theranostic compound
into widespread clinical use.
One existing challenge stemming from the exposed gold and
its associated high surface binding energy to biological milieu is
the adsorption of proteins that aﬀects nanoparticle−cell
interactions.22 To date almost 120 human plasma proteins
have been shown to bind with AuNPs.23 Protein adsorption
prevents rapid aggregation but does not preclude high uptake in
the reticuloendothelial system with a concomitant intra-
endosomal aggregation in the cells. Consequently, the resultant
toxicity of AuNPs5,24 in vivo is dramatically increased.
Moreover, noninvasive RF cancer therapy is less eﬀective at
inducing targeted hyperthermia when the AuNPs are
aggregated,25,26 which could limit the usefulness of AuNPs
for RF-ablative therapies. Similar to well-known strong thiol−
gold interactions, charge-neutral amine/gold surface interac-
tions (which are comparable to weak covalent bonds between
gold atoms and the nitrogens of amines27) are capable of
supporting stabilizing layers on gold nanoparticles. We
hypothesized that methoxy(polyethylene glycol)-polylysine
conjugates, i.e., MPEG-gPLL graft copolymers that were
previously extensively used for delivery of imaging probes
(reviewed in ref 28), have a potential use in AuNP stabilization.
This potential stems from the relative strength of amine−gold
interactions combined with a level of cooperativity of gold
interactions with multiple amino groups carried by a single
MPEG-gPLL molecule. Therefore, in our work we set forth to
(1) investigate the ability of MPEG-gPLL to stabilize and
simultaneously to functionalize AuNPs by providing a plurality
of amino groups available for further facile conjugation of
various ligands to the surface of nanoparticles, and (2) test the
heating and electrical properties of the obtained nonaggregating
AuNPs for future applications in minimally invasive cancer
therapy.
■ RESULTS
Synthesis and Characterization of MPEG-gPLL and
AuNPs. By using alternative conjugation chemistries for
Figure 1. Synthesis and optical properties of MPEG-gPLL-stabilized gold nanoparticles (AuNPs). (A) Schema of water phase synthesis of AuNPs
using capping/stabilizing MPEG-gPLL graft copolymer and optional trisodium citrate, n = 110, m=164. (B) Image of the PCR well-plate acquired
after the synthesis of AuNPs in the presence of various concentrations of HAuCl4 and MPEG-gPLL. (C) Comparative absorbance spectra showing
the positions and intensities of the GNP plasmon peaks measured in the wells of the plate shown in (B) with the corresponding well series indicated
on the right.
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grafting MPEG5 chains to a PLL backbone (Supporting
Information Figure 1S) we obtained graft-copolymers with
MPEG chains linked via either very stable urethane bonds
(MPEG-gPLL1) or less stable amide bonds with an additional
labile ester bond in the MPEG chain (MPEG-gPLL2). Both
MPEG-gPLL1 and MPEG-gPLL2 had excellent solubility in
water in the pH range of 3−9 and were eluted on Superdex 200
as single peaks (Supporting Information Figure 2S, A). The
analysis of the structure of the obtained copolymers showed the
presence of all the anticipated structural blocks (Supporting
Information Figure 2S, B and C). The PEGylation degree was
determined by integrating the total area of ε-CH2 proton peaks
corresponding to free and acylated lysine side-chains and
calculating the fraction of acylated side chains. For example,
Supporting Information Figure 2S shows MPEG-gPLL with a
PEGylation degree of 30%. The synthesized MPEG-gPLL1 and
2 contained approximately 25% MPEGylated N-ε-amino
groups. Higher numbers of conjugated MPEG5 chains, i.e.,
more than 30% of the available N-ε-amino groups of PLL,28
resulted in graft-copolymers that did not support the
stabilization of AuNPs.
To synthesize MPEG-gPLL-stabilized AuNP we tested
several protocols that included (1) the coaddition of MPEG-
gPLL and 3.5 mM trisodium citrate to the solution of HAuCl4
at 95 °C (Figure 1A); (2) the addition of MPEG-gPLL in the
absence of citrate at 95 °C; or (3) stabilizing AuNPs by adding
MPEG-gPLL at 95 °C to freshly prepared citrate-stabilized
AuNPs.29 All tested protocols resulted in AuNPs with very
similar properties regardless of whether MPEG-gPLL1 or
MPEG-gPLL2 was used for nanoparticle stabilization. How-
ever, the yields of nanoparticle synthesis were 1.5-fold higher in
the presence of trisodium citrate. In the absence of citrate the
AuNPs formed much more rapidly: it took 2 min in the absence
vs 30 min in the presence of 3.5 mM trisodium citrate to obtain
nanoparticles with a characteristic absorbance peak at 525 nm
in a volume of 10 mL. The presence of free amino groups in
MPEG-gPLL was essential for obtaining stable and spherical
nanoparticles (Table 1). Succinylated or acetylated MPEG-
gPLL1 (i.e., with all free amino groups of MPEG-gPLL1
covalently blocked) did not support the formation of spherical
AuNPs and resulted mainly in the formation of 2:1 aspect
nanorods (Table 1) with plasmon peak widening and shifting
to 575 nm. In control experiments, the addition of the excess of
amino-terminated MPEG5000 together with citrate during the
synthesis of AuNPs did not result in stable nanoparticles. To
obtain the amino-containing AuNPs (AuNP4) stabilized with
an oriented MPEG layer we used a mixture of MPEG-thiol and
amino-PEG-thiol (1:1, by weight) added in the presence of 3.5
mM trisodium citrate during synthesis of AuNP.
We further studied the eﬀect MPEG-gPLL1 graft copolymer
and the concentration of HAuCl4 on AuNP formation using a
PCR plate format and a Peltier device with rapid heat exchange
(Figure 1B). In order to determine conditions that would result
in the formation of AuNPs with the optimal dynamic light
scattering and highest plasmon peak intensity characteristics
(Figure 1B,C), we varied the concentration of HAuCl4 (80 to
160 μM) and of MPEG-gPLL1 (0.3 to 2.4 mg/mL) during
synthesis. The results of these titrations showed that the
acceptable concentration range for HAuCl4 was 140−160 μM,
while the MPEG-gPLL1 concentration had to be kept above 0.3
mg/mL (Figure 1C).
The AuNP synthesis performed in the presence of 0.14 mM
HAuCl4, i.e., at the intermediate tested concentrations of T
ab
le
1.
P
ro
pe
rt
ie
s
of
A
uN
P
U
se
d
in
T
hi
s
W
or
k
sa
m
pl
e
de
sc
rip
tio
n
hy
dr
o-
dy
na
m
ic
di
am
et
er
,(
by
pe
ak
in
te
ns
ity
),
nm
m
ea
n
±
SD
(P
D
I)
go
ld
co
re
si
ze
,n
m
,
m
ea
n
±
SD
,
ag
gr
e-
ga
tio
n
in
PB
S,
pH
7.
4
re
te
nt
io
n
on
B
io
-G
el
P3
0
m
ea
n
di
am
et
er
±
SD
ze
ta
-p
ot
en
tia
l
(m
V
),
m
ea
n
±
SD
am
in
o
gr
ou
ps
A
uN
P
N
a 3
ci
tr
at
e-
ca
pp
ed
13
.6
±
11
.0
(0
.2
2)
13
.0
±
4.
8
ye
s
Y
es
0.
68
±
0.
14
−
21
.0
±
10
.0
N
D
A
uN
P2
(n
an
or
od
s
2:
1)
N
a 3
ci
tr
at
e
fo
llo
w
ed
by
su
cc
in
yl
at
ed
M
PE
G
5-
gP
LL
1
64
.9
±
20
.7
(0
.3
4)
N
A
no
Y
es
−
4.
4
±
7.
8
N
D
A
uN
P3
N
a 3
ci
tr
at
e
fo
llo
w
ed
by
M
PE
G
5-
gP
LL
1
or
M
PE
G
-g
PL
L2
36
.9
±
12
.8
(0
.2
7)
10
.4
±
2.
5
no
N
o
49
.6
±
17
.6
+3
.7
±
9.
8
1
μm
ol
/
A
U
*
A
uN
P4
N
a 3
ci
tr
at
e
fo
llo
w
ed
by
SH
-P
EG
5-
N
H
2
an
d
M
PE
G
5-
SH
98
.6
±
28
.1
(0
.2
2)
N
A
ye
s
Y
es
34
.9
±
9.
8
−
2.
2
±
5.
8
0.
2
m
m
ol
/
A
U
*
R
bM
P-
A
uN
P3
A
uN
P3
w
ith
co
va
le
nt
ly
lin
ke
d
rib
oﬂ
av
in
m
on
op
ho
sp
ha
te
55
.1
±
16
.2
(0
.3
0)
9.
3
±
2.
6
no
N
o
44
.8
±
10
.7
−
12
.9
±
7.
0
N
D
*
M
ol
es
pe
r
ab
so
rb
an
ce
at
53
0
nm
(a
rb
itr
ar
y
un
its
),
N
D
-
no
t
de
te
ct
ab
le
.
Bioconjugate Chemistry Article
dx.doi.org/10.1021/bc5005087 | Bioconjugate Chem. 2015, 26, 39−5041
HAuCl4 and MPEG-gPLL (0.9 mg/mL), resulted in nano-
particles with gold cores of 10.4 ± 2.5 nm diameter as
determined by transmission electron microscopy (TEM, Table
1 and Figure 2E) and an average eﬀective hydrodynamic
diameter of 36.9 nm due to the presence of the coating layer on
their surface (“AuNP3”, Table 1). Compared to highly
negatively charged citrate-capped AuNPs, AuNP3s were weakly
positively charged and carried reactive amino groups (Table 1).
The combined evidence of laser light scattering and zeta-
potential measurements pointed to the presence of small (6−7
nm) and strongly positively charged molecules of MPEG-
gPLL1 that were initially present in AuNP3 reaction mixtures
after the synthesis (Figure 2A,C). MPEG-gPLL1 peaks were
undetectable in AuNP3 samples following puriﬁcation by
gradient ultracentrifugation and/or ultraﬁltration (Figure
2B,D). Ultracentrifugation performed in a step-gradient of
nonionic iodixanol allowed separation of MPEG-gPLL-
stabilized AuNPs from the bulk of nonbound MPEG-gPLL
and enabled the quality of puriﬁcation to be controlled by
analyzing the individual fractions for the presence of amino
groups and intensity of AuNP plasmon peak (Supporting
Information Figure 4S). Puriﬁed MPEG-gPLL1-stabilized
AuNP3s did not aggregate in the presence of phosphate anions
(PBS, Table 1), nor did they show adsorption on the surface of
polysaccharide microporous (i.e., BioGel P-30) and macro-
porous gel-ﬁltration beads. This allowed the use of size-
exclusion chromatography for purity analysis and for
puriﬁcation of AuNP3s from low molecular weight impurities
after covalent modiﬁcation.
The structure and composition of the MPEG-gPLL1 coating
surrounding the synthesized AuNP3s was studied in more
detail using electron microscopy and gravimetric analysis. TEM
of samples following uranyl acetate negative staining revealed
the presence of a 9-nm-thick polymer layer on the surface of
the AuNP3s that was contrasted with uranyl acetate (Figure
2F). The estimated total diameter of dehydrated AuNP3s (i.e.,
the core surrounded by the stabilizing layer) was 30.0 ± 4.6
nm. On scanning electron microscopy (SEM) images (Figure
2G), the layer of MPEG-gPLL1 on the surface of nanoparticles
was clearly visible and took the appearance of a halo around the
gold cores which could easily be identiﬁed within the coating
layer in the backscattering SEM mode. According to
thermogravimetry results, puriﬁed and lyophilized AuNP3s
contained 34% gold by weight with the rest of the weight
balance consisting of hydrated MPEG-gPLL1.
The feasibility of conjugating amine-reactive compounds to
the free amino groups of MPEG-gPLL1 attached to AuNPs was
tested by linking riboﬂavin monophosphate (a small negatively
charged ligand) using water-soluble carbodiimide. A facile
covalent conjugation of phosphate groups to the surface of
AuNP3s resulted in phosphamides and a resultant shift of
AuNP3 zeta potential from weakly positive to negative (i.e.,
from average +3.7 to −12.9, Table 1).
Stability and Behavior of MPEG-gPLL-Stabilized
AuNPs in Biological Systems. The presence of a layer of
Figure 2. Properties of AuNP3 stabilized with MPEG-gPLL. (A,B) Z-average hydrodynamic diameter (LALLS intensity, solid lines) and number size
distribution of puriﬁed AuNP3 (panel B, hatched line). (C,D) Zeta potential (charge) of AuNPs before (A,C) and after (B,D) the puriﬁcation. (E)
Representative ﬁeld of view showing the results of transmission electron microscopy of AuNP3s; inset - AuNP3 diameter distribution calculations
using image segmentation analysis of large number (n = 360) of AuNP3 gold cores. (F) Uranyl acetate-enhanced contrast staining of the sample
shown in panel E. (G) Backscatter (compositional) scanning electron microscopy image of the glass-adsorbed AuNP3.
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MPEG-gPLL1 or MPEG-gPLL2 graft copolymers bearing
reactive amino groups suggested that MPEG-gPLL stabilized
AuNP could potentially be covalently modiﬁed with activated
esters of chelates and then labeled with radioactive isotopes for
investigating the biodistribution of nanopartciles and tracking
the stability of their coating in vitro and in vivo. Initially, we
studied the stability of both MPEG-gPLL1- or MPEG-gPLL2-
stabilized AuNPs. The particles were covalently modiﬁed with
S-AcMAG3-NHS, i.e., with S-acetylmercaptoacetyltriglycine
residues (S-AcMAG330) that enabled stable labeling of
AuNPs with 99mTc using [99mTc]-pertechnetate reduction
(Figure 3, Supporting Information Figure 5S). The AuNP
showed stability of labeling with 99mTc even after 22 h
incubation in PBS and the total loss of radiolabel did not
exceed 4% in both cases. The released 99mTc (as pertechnetate)
appeared as minor peaks eluted in the total volume of the
column (Figure 3 and Supporting Information Figure 5S). The
incubation in the presence of blood plasma at 37 °C resulted in
a much greater degree of fragmentation of the MPEG-gPLL2
coating of AuNPs (Supporting Information Figure 5S) than
AuNPs stabilized with MPEG-gPLL1: the latter showed no
more than 8% loss of 99mTc in the presence of plasma (Figure
Figure 3. Stability of AuNP3 protective layer. Size-exclusion HPLC proﬁles of 99mTc-AuNP3 stabilized with MPEG-gPLL1 that were incubated for 1
and 22 h either in PBS or 75% mouse plasma. HPLC was performed on Superose 6 10/300 GL HPLC size-exclusion column eluted with 20%
acetonitrile in 0.1 M TrisHCl, pH 8.0 (0.6 mL/min).
Figure 4. Cell uptake of AuNP3s and cytotoxicity. (A) TEM results showing the presence of individual nonaggregated AuNP3s in the endosomes
(arrowhead). (B) Fusion of endosomes (arrowhead) with the lysosome (arrow) coinciding with microaggregation of AuNPs. (C) Gold
concentration-dependent cytotoxicity measured in cell culture of normal human endothelial cells (black), HeLa cells (blue), and PANC-1 cells (red).
(D) Uptake of AuNP3 and control MPEG-thiol stabilized AuNP4 in HeLa, PANC-1, and normal human endothelial cells expressed as the amount of
gold taken up per million cells in culture within 24 h. The uptake of AuNP3s was signiﬁcantly diﬀerent between all three cell lines.
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3). The stability testing of graft copolymers alone (i.e., 99mTc-
labeled and puriﬁed MPEG-gPLL1 and MPEG-gPLL2) in PBS
and in the presence of plasma revealed fragmentation of the
polymers in the presence of plasma and a lack of fragmentation
in PBS at 22 h (Supporting Information Figure 3S). However,
there was less fragmentation observed in the presence of plasma
in the case of MPEG-gPLL1, which dictated selecting MPEG-
gPLL1 as the preferred graft copolymer for nanoparticle
stabilization in further experiments.
To investigate whether MPEG-gPLL1-stabilized AuNP3s
were taken up by normal and cancer human cells in vitro, the
nanoparticles were membrane-sterilized and incubated with
cells in complete medium (i.e., in the presence of 10% serum)
at various concentrations. The measurements of cellular uptake
in two cancer cell lines (HeLa, PANC-1) and normal human
umbilical vein endothelial cells (HUVEC) showed that cancer
cells internalized AuNPs at the following descending order of
the uptake of the added amount of AuNPs (concentration
range 10−100 μg Au/mL) to diﬀerent extents with the highest
to lowest being HeLa (0.74 ± 0.21%) > PANC-1 (0.70 ±
0.31%) > HUVEC (0.19 ± 0.04%). The uptake in HUVECs
was signiﬁcantly (p < 0.05) lower than in epithelioid cancer cell
lines. TEM investigation of the uptake revealed the presence of
AuNPs in endosomes of cancer cells with most of the
nanoparticles exhibiting no binding to the luminal surface of
endosomes (Figure 4A). Conversely, in organelles that
underwent fusion with lysosomes, nanoparticles appeared
more aggregated and associated with the membranes (Figure
4B). PANC-1 cancer cells that showed the highest average level
of AuNP3 uptake also exhibited dose-dependent toxicity (50%
cell survival at 500 μg Au/mL) whereas normal human
endothelial cells exhibited only an 8 ± 2% decrease of cell
viability at the same dose (Figure 4C). The low toxicity of
AuNP3s for normal endothelium correlated with low uptake of
AuNP3s and MPEG-stabilized AuNP 4s (Figure 4D). The
uptake of AuNP3s in HeLa cells and PANC-1 was signiﬁcantly
higher and diﬀerent for all three cell lines (P = 0.045), whereas
AuNP4 were taken up at the same levels in epithelial cancer
cells and HUVEC (P = 0.33).
The covalent modiﬁcation of the MPEG-gPLL1 layer by
conjugating S-AcMAG3 residues to the surface of AuNP3s
enabled subsequent [99mTc] labeling of nanoparticles with high
yields; the labeling eﬃciency was in the range of 75−90% of
initially added radioactivity. We used [99mTc]-AuNP3 for in
vivo studies that included longitudinal in vivo SPECT imaging
and biodistribution experiments. The imaging was performed in
Figure 5. In vivo imaging showing biodistribution and biokinetics of 99mTc-AuNP3. (A−C) SPECT/CT imaging of 99mTc-AuNP3 in mouse model
of local sterile inﬂammation in the right extremity at 0.2 (A), 4 (B), and 24 h (C). Coronal maximum intensity pixel projection (MIP) SPECT
images fused with CT images at a 600 μCi of 99mTc-AuNP3 are shown in the left column and representative coronal slice images showing the
accumulation of AuNP3 in femoral muscle are shown in the right column. Accumulation in the aﬀected muscle is denoted by arrowheads. The
pseudocolor scale representing dose distribution in image voxels is shown on the right. (D) Transverse projection image slice (left) and MIP image
(right) of the LPS injected and control contralateral femoral muscle. The accumulation of AuNP3s in the area of inﬂammation is denoted by
arrowheads. (E) Time-dependent increase of the ratio between signals measured in the inﬂamed and normal contralateral muscle over time.
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a DBA/2 mouse model of locally induced inﬂammation and in
tumor xenograft-bearing athymic mice. Imaging results were
corroborated by biodistribution measurements using both
decay-corrected 99mTc radioactivity counts and inductively
coupled plasma mass spectrometry (ICP-MS) to measure gold
content. Noninvasive SPECT imaging of 99mTc-AuNP3 showed
that after the IV injection the major fraction of the injected
radioactivity was contained within the blood pool of mice for an
extended period of time (24−26 h, Figure 5). The SPECT
imaging results were corroborated by measuring the radio-
activity in the blood pool and other major organs (Figure
6A,B). The half-life of 99mTc-AuNP3 elimination from blood
was concentration-dependent and the elimination rate showed
ﬁrst-order kinetics (Figure 6A). Blood sampling followed by
separation of blood cells and plasma showed that 89−94% of
99mTc radioactivity in the blood was associated with plasma and
6−11% with red blood cells and leucocytes. Size-exclusion
chromatography of mouse plasma and urine samples obtained
in vivo at 4 h post IV injection of 99mTc-AuNP (Supporting
Information Figure 6S) demonstrated that AuNP3 in plasma
retained 99mTc radioactivity, which was eluted as single peaks
identical to the initially injected AuNP3 while low 99mTc
radioactivity present in urine was due to the excretion of the
fragments of the radioactively labeled MPEG-gPLL1 layer.
Only the urine collected from the animals injected with a high
dose of AuNP had a minor fraction eluting close to the void
volume (Supporting Information Figure 6S). The ICP-MS data
showed that with the exception of blood (where the mass of
nanoparticles predicted from 99mTc radioactivity counts was
only 20% lower than determined by ICP-MS) the actual gold
content in all other major organs was 2−5 times higher than
the organ uptake determined based on counts of radioactivity
linked to the gold nanoparticle-stabilizing MPEG-gPLL1 layer
(Figure 6C).
In experimental disease models, the amounts of AuNP-
associated 99mTc radioactivity detected in the areas of enhanced
vascular permeability, i.e., in the experimental inﬂammatory
lesions, as well as in PANC-1 tumors (Supporting Information
Figure 6. Kinetics of AuNP3 elimination from blood and biodistribution. (A) Blood half-lives determined from a monoexponential ﬁt of 99mTc-
AuNP radioactivity elimination injected at two doses: low − 0.2 mg Au/kg (n = 5/goup); high − 5 mg Au/kg (n = 5/group), r2 = 0.72−75. (B)
Biodistribution in major mouse tissues expressed as fractional dose per gram of tissue weight (n = 5) at low (hatched bars) and high (gray bars) dose
of AuNP3 injected I.V. (C) Comparison of AuNP3 biodistribution in the high dose (5 mg Au/kg) animals (n = 4) shown as % injected dose/organ
using 99mTc radioactivity (gray bars) and ICP-MS data (black bars).
Figure 7. RF heating and electrical properties of AuNP3s compared to citrate-capped AuNPs. Temperature increase (A) and loss tangent (ε″) (B) of
AuNP3 solution (0.75 mg gold/mL) versus control (buﬀer). Dotted line in (B) shows 13.56 MHz RF operating frequency. (C) Diﬀerential heating
rates of citrate capped AuNPs (average core diameters 5 and 10 nm) compared to AuNP3 (average core diameter 10.4 nm).
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Table 1S) were higher than in control tissues. The target-to-
background ratio (i.e., the ratio of normalized radioactivity
measured in inﬂamed extremity versus control nonaﬀected
muscle) increased over time and ranged from 5.2 to 6.1 in areas
of inﬂammation (Figure 5E). Likewise, PANC-1 tumors also
showed a markedly increased accumulation of long-circulating
AuNP3s with the target-to-background ratio ranging between 2
and 4.
Evaluation of AuNP3s for RF Ablation Applications.
We evaluated the use of AuNP3s as a potential vector for
applications in noninvasive RF cancer therapy. Figure 7A
depicts the temperature data of both citrate-buﬀered solution of
AuNP3 and the same buﬀer solution lacking AuNP3. The latter
was exposed to the RF ﬁeld after the AuNP3s were separated
via ultraﬁltration to separately account for ionic Joule heating of
the buﬀer solution. The electrical permittivity properties of the
samples were then examined using a permittivity analyzer
across the frequency range 10 MHz to 1 GHz. As can be seen
in Figure 7B, there is a diﬀerence in loss tangent (ε″) between
the AuNP3s and the buﬀer solution, which suggests that
AuNP3s will act as a lossy dielectric, i.e., liberating heat when
exposed to a radiofrequency range electromagnetic radiation
(as is shown in Figure 7A). The diﬀerential heating rates of
weakly positively charged AuNP3s were then compared to
highly negatively charged citrate-capped AuNPs (having
diameters 5 and 10 nm) at a similar concentration of particles
(Figure 7C). We observed heating proﬁles that were similar to
those of citrate-capped AuNPs of diameter 10 nm. This result is
in agreement with our EM measurements of AuNP3 gold core
diameters as being approximately 10 nm (Table 1).
■ DISCUSSION
The goal of our study was to explore the use of a highly
hydrophilic covalent graft copolymer of methoxy poly(ethylene
glycol) and polylysine (MPEG-gPLL) as a potential stabilizing
macromolecule for improving biocompatibility of AuNPs.
“Stabilization”, i.e., the consequences of intentional decrease
of the uniquely large surface energy of gold nanoparticles, has
been explored by numerous research groups in the past.4,5,31
These past eﬀorts included the use of copolymers containing
poly(ethylene glycol)32,33 as a biocompatible synthetic
component with controllable structure and length capable of
eﬃcient masking of the nanoparticle surface and enabling
further potential functionalization of the protective layer.34
Similarly, the rationale for the use of MPEG-gPLL lies in its
biocompatibility and in its capacity to drastically decrease the
immunogenicity of any molecule covalently linked to the amino
groups of the PLL backbone.35 Initially designed for MRI,35
MPEG-gPLL has to date been used for multiple applications in
biomedicine and serves as a highly versatile and nontoxic
platform for synthesis of a multitude of macromolecular drugs
and drug formulations (reviewed in refs 28,36) as well as a gene
delivery carrier.37 The potential beneﬁts of using MPEG-gPLL
instead of thiol-PEG or other poly(ethylene oxide) copolymers
in AuNP synthesis include: (1) the plurality of free N-ε-amino
groups in MPEG-grafted PLL enable cooperative interactions
with the gold surface; (2) the “built-in” MPEG protective
elements in MPEG-gPLL obviate the need for subsequent
modiﬁcation; (3) the residual amino groups carried by MPEG-
gPLL-protected AuNPs enable conjugation to other molecules;
and ﬁnally, (4) MPEG-gPLL has proven viable as a platform for
diagnostic drug development and has performed successfully in
past clinical trials.38
We investigated in vitro and in vivo properties of AuNPs that
were synthesized in the presence MPEG-gPLL, with or without
sodium citrate. We established that, indeed, during water-based
synthesis the presence of multiple free amino groups in MPEG-
gPLL was essential for the formation and stabilization of small
and spherical AuNPs (with 10.4 ± 2.5-nm-diameter cores,
termed AuNP3), suggesting a critical role for multiple amino
groups in stabilization of ﬁnite-sized gold surfaces. This was
further evidenced by the fact that, after the covalent blocking of
the amino groups or after converting MPEG-gPLL into a
polyanion by succinylation, the formation of spherical particles
was no longer favorable (Table 1). Previous eﬀorts of gold
nanoparticle stabilization in the presence of aliphatic mono-
amines showed that the stabilizing properties of monoamines
could be explained by a charge-neutral amine/gold surface
interaction that was comparable to weak covalent bonds
between gold atoms and the nitrogens of amines.27 In the case
of MPEG-gPLL, multiple amine−gold interactions add
cooperativity of copolymer−gold surface interaction that is
clearly responsible for the observed stability of AuNP3s against
aggregation in the presence of phosphate anions and blood
plasma (Table 1, Figure 3). Electron microscopy data pointed
to the presence of a layer of MPEG-gPLL on the surface of
AuNP3 cores that had a thickness comparable to the gold core
diameter (i.e., approximately 9-nm-thick coat vs 10.4 nm core
diameter on average), which was in accordance with the results
of thermogravimetric analysis.
The next step of AuNP3 testing involved cell culture
experiments that suggested overall lower in vitro uptake of
MPEG-gPLL-stabilized nontargeted nanoparticles in normal
endothelial vs epithelial cancer cells. The overall levels of
uptake in cell culture were proportional to the concentration of
gold in the incubation media. It should be noted that AuNP3
(which unlike control PEG-thiol stabilized AuNP4 bear weak
positive charge) had higher levels of uptake in PANC1 and
HeLa cells (Figure 4D). The latter cells overexpress negatively
charged heparan sulfate proteoglycans.39,40 Therefore, diﬀer-
ences in the rate of charge-dependent adsorptive endocytosis
between cancer cells and normal endothelium is a plausible
explanation for the diﬀerential uptake of weakly positively
charged AuNP3s in cancer cells. Enhanced water phase
endocytosis (pinocytosis) of AuNPs, previously shown to be
coupled to Rac1/Ras activation in cancer cells41,42 apparently
played a less important role considering that normal human
endothelial cells showed low uptake of AuNPs regardless of
particle coating layer (Figure 4D) and that the uptake of
control AuNP4 in normal endothelial cells and epithelioid
cancer cells was almost identical. Importantly, the higher
observed uptake of AuNP3 in cancer cells compared to normal
endothelial cells was associated with pronounced toxicity
(Figure 4C) suggesting a potential theranostic use of these
gold nanoparticles.
Further, we tested whether the dense coating of AuNP3 with
PEGylated copolymer would promote long circulation and
extravasation in animal models of experimental sterile
inﬂammation (myositis) and cancer (PANC-1 xenograft
model). In vitro testing of AuNP3s that were stabilized with
stable MPEG-gPLL1 copolymer retained integrity in plasma or
PBS for at least 22 h (Figure 3), which suggested a potential for
long circulation of AuNP3s in vivo. The IV administration of
[99mTc]-labeled AuNP3s in mice resulted in excellent blood
pool contrast: even at a low injected dose of gold (0.2 mg/kg)
AuNP3 showed a half-life of 9.7 h in circulation while a
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continuous time-dependent accumulation in the area of
experimental inﬂammation was clearly evident (Figures 5 and
6). It should be noted that long circulation with a plasma half-
life of 14.6 ± 3.3 h (ﬁrst-order elimination in vivo) has been
reported previously in mice after an I.V. injection of 1500 times
higher doses of MPEG-thiol stabilized AuNPs for CT imaging
(0.6 g gold/kg body weight).10 Our data suggests that the
MPEG-gPLL1 layer is also capable of providing AuNPs with
eﬃcient protection against rapid clearance in vivo with the
additional beneﬁt of multiple free amino groups available on
AuNP3 surface for modiﬁcation with other adaptor molecules
including targeting ligands. However, the use of the MPEG-
gPLL1 layer did not prevent the in vivo uptake of a minor
fraction of AuNP3 that was retained in the organs of
reticuloendothelial system either as a result of incomplete
coating, or as a result of constitutive uptake from plasma with
subsequent degradation of the stabilizing layer of MPEG-
gPLL1 (Figure 6C).
The in vivo results obtained in mouse models are clearly
relevant to the proposed use of AuNPs as vectors for
noninvasive RF radiation-induced ablation of solid tumors
that require lossy dielectric nanoparticles25 (see Figure 7). The
prevention of aggregation of these particles is especially critical,
since in addition to size, concentration of gold, and the
presence of surface charge the heating rates of AuNPs were
shown to be negatively aﬀected by the presence of particle
aggregates in target cancer cells.25 The time selected for RF
exposure and the AuNP concentrations were similar to those
used in vivo by our group previously15 in which case it was
conﬁrmed that a 10 min RF exposure of mice injected with
AuNP conjugates did not cause any serious damage to vital
organs. We anticipate that the levels of AuNPs in organs will be
low (Figure 6 B,C), and due to the normal function of
vasculature in these organs, the heating will be dissipated by
intensive circulation. In tumors the blood vasculature is slow
and ineﬃcient, and therefore, heat dissipation is ineﬀective43
causing a localized tumor-speciﬁc RF-induced hyperthermia.
Further work is currently underway to assess the RF-induced
heating eﬃcacies of AuNP3 in both in vitro and in vivo
environments.
■ CONCLUSIONS
In conclusion, coating of AuNPs with a layer of biocompatible
graft copolymer during synthesis in the water phase resulted in
nanosized single core nanoparticles exhibiting a highly
improved stability in solutions containing physiological anions.
The improved stability in biological ﬂuids and, as a
consequence, long circulation times in vivo were observed in
the case of AuNP3 coated with more stable MPEG-gPLL
lacking ester bonds. The ability of AuNP3s to accumulate at the
sites of abnormal vascular permeability such as sterile
inﬂammation in vivo while resisting aggregation after cellular
uptake makes them useful for inducing either direct or RF
heating-induced cytotoxicity in cancer cells and suggest the
substantial therapeutic and diagnostic potential of AuNP3s. In
the future, the ability to ﬁne-tune the number of chemically
reactive amino groups on the surface of AuNP3s as well as
AuNP core diameters will allow us to further functionalize these
nanoparticles and improve the selectivity of their accumulation
in tumors, as well as their RF heating rates, thus making them
suitable for treating cancer by using localized RF therapy. At
the same time, our research demonstrated that the chemistry of
stabilizing graft copolymer can be potentially used as a tool for
optimizing the required in vivo stability by making the
stabilizing layer on the surface of AuNP either more susceptible
or more resistant to biodegradation.
■ EXPERIMENTAL PROCEDURES
Synthesis of Gold Nanoparticles. (1). Optimization in
PCR Plate Format. MPEG-gPLL1 (PLL grafted with MPEG-
carboxymethyl-NHS ester) was synthesized and puriﬁed as
described in the Supporting Information. MPEG-gPLL1 (120
mg/mL in 35 mM trisodium citrate) was serially diluted 2× in a
96-well titer plate. HAuCl4 solution was diluted to 160, 140,
110, and 80 μM in H2O. 0.2 mL of these solutions were placed
in polypropylene PCR plates (USA Scientiﬁc), sealed, and
heated to 95 °C using a PCR Peltier thermocycler (PTC-200,
MJ Research, Watertown MA). After 5 min, 20 μL of serially
diluted solutions of MPEG-gPLL1 were added to the wells of
the PCR plate using a multipipette and the plate was resealed
and heated at 95 °C for an additional 30 min.
In order to establish the position of the AuNP plasmon
resonance peak, the plate was quickly cooled to 0 °C in the
thermocycler unit and the contents of the wells were
transferred to 96-well plates to measure the absorbance spectra
in the range of 400−700 nm using a Spectramax M5 plate
reader (Molecular devices).
(2). General AuNP Scale-Up Synthesis Procedure. A 0.14
mM solution of HAuCl4 was prepared in 100 mL of degassed
deionized H2O saturated with nitrogen, using an internal probe
to monitor temperature. The solution was quickly heated to 95
°C for 5 min using a water jacket, and subsequently a solution
of MPEG-gPLL1 or MPEG-gPLL2 (26 mg/mL in 0.1 M
trisodium citrate) was injected into the solution of HAuCl4 in a
volume of 3.5 mL with stirring. In some experiments the
synthesis was performed in the absence of trisodium citrate by
using a solution of MPEG-gPLL in water (26 mg/mL). The
ﬁnal concentration of residual amino groups in the AuNP
reaction mixture was approximately 0.4 mM. The heating
continued for 15 min and the AuNP reaction mixture was
immersed in an ice/water mixture followed by ﬁltering through
a 0.22 μm membrane using sterile Steriﬂip-GV PVDF
membrane units (Millipore) for storage prior to the
puriﬁcation. To obtain control MPEG-coated AuNPs
(AuNP4), HAuCl4 solution (0.14 mM, 100 mL) was treated
with a mixture of 50 mg/mL mono aminePEG5000-thiol and
50 mg/mL MPEG5000 thiol (JenKem Technology, Allen TX)
in 3.5 mL of 0.1 M trisodium citrate that was added to HAuCl4
solutions in place of MPEG-gPLL1 or MPEG-gPLL2.
Puriﬁcation of AuNPs. The separation from free MPEG-
gPLL was accomplished by loading 1 mL of AuNP3s
concentrated in Amicon Ultra 4 YM-100 centrifuge membrane
concentrators (EMD-Millipore, Billerica MA) on top of a step-
gradient consisting of 0.2 mL 50% Opti-Prep (60% Iodixanol
solution in saline, Sigma-Aldrich, St. Louis MO) with the initial
density 1.32 g/mL, followed by 4 mL of 8% solution of Opti-
Prep in 0.03 M Hepes, pH 7.5, and centrifuged in a SW55.1 Ti
rotor (Beckman) at 40 000 rpm (RCF 152 000 g) for 40 min.
The bottom 0.4 mL fraction was collected, vortexed, and
washed with 20 mM Hepes, 0.1 M NaCl, pH 8.0 using Amicon
Ultra 4 YM-100 centrifuge membrane concentrators as
suggested by the manufacturer. After the washings, the particles
were pooled and lyophilized. The lyophilized particles were
reconstituted in water at 10 mg/mL for further experiments.
Before thermogravimetric analysis, extensively dialyzed and
lyophilized AuNP3 were dried under high vacuum for 3 days.
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The purity of nanoparticles was determined using a Superdex
200 size-exclusion HPLC column (GE-Healthcare Life
Sciences) eluted with 0.1 M ammonium acetate buﬀer, pH 7.0.
Linking of MAG3-NHS Ester to AuNPs and 99mTc
Labeling. The covalent modiﬁcation of MPEG-gPLL AuNPs
with S-mercaptoacetyldiglycylglycine NHS ester, (S-AcMAG3-
NHS, Kerafast, Boston MA) was performed as described.44
Nonbound MAG3 was removed using Bio-Spin30 centrifuga-
tion minicolumns (Bio-Rad) as described by the manufacturer,
or on a Sephadex G25m 10 × 1 cm column (Sigma-Aldrich)
using gravity size-exclusion chromatography. The labeling
procedure that involved the reduction of 99mTc(VII)
pertechnetate with Sn(II) with simultaneous deprotection of
thiols is described elsewhere.44 The radiolabeling purity was
determined using ITLC-G and size exclusion HPLC on a
Superose 6 10/300 GL column (GE-Healthcare Life Sciences).
The stability of labeling was tested by incubating 99mTc-labeled
AuNP3 in the presence of 75% mouse plasma with subsequent
analysis of samples using a Superose 6 10/300 GL column.
Conjugation of Riboﬂavin-5′-Monophosphate. Con-
jugation of RbMP was accomplished using phosphamide bond
formation as suggested in ref 45. Brieﬂy, 0.07 mmol of RbMP in
0.5 mL of 0.2 M 1-methylimidazole was mixed with 0.14 mmol
of EDC in 0.5 mL water on ice for 10 min and the resulting
mixture was added to 0.2 mL of AuNP3 (1 mg solid) dissolved
in 0.2 M NaHCO3. The RbMP-conjugated nanoparticles were
puriﬁed by dialysis and the absorbance ratios at 445 and 525
nm (i.e., plasmon peak maximum) were determined for the
control and conjugated AuNPs, respectively. The extinction
coeﬃcient of RbMP at 445 nm is 13 000 [mol·cm]−1.
Cell Culture Experiments. These were performed in
human umbilical vein endothelial cells (HUVEC), HeLa, and
PANC-1 cells. HUVEC cells were grown in 5% FBS and
complete endothelial cell growth medium (EGM, Cambrex,
Baltimore, MD) until conﬂuent. PANC-1 cells were grown in
10% FCS and DMEM and HeLa cells were grown in 10%
EMEM. Cells were incubated for 24 h with various
concentrations of AuNP3, [99mTc]-labeled AuNP3s, or
[99mTc]-labeled AuNP4 after which cell uptake was determined
by gamma counting of HBSS-washed cell suspensions and
cytotoxicity was determined in attached cells. Cytotoxicity was
measured using a 96-well format and a standard WST reagent
assay by measuring the formation of red formazan compound at
500 nm using a plate reader. The WST signal was normalized
using background (reference) measurements at 650 nm.
High-Resolution Transmission Electron Microscopy.
TEM characterization of nanoparticles was performed by
incubating AuNPs diluted with 1:10 PBS on Formvar coated
grids stabilized with evaporated carbon ﬁlm with or without
negative staining with 1% uranyl acetate and further
examination under EM (FEI Tecnai 12 Spirit, at 100−140 K
magniﬁcation). SEM experiments were performed using a FEI
Quanta 200 FEG MKII scanning electron microscope.
Nanoparticle core size measurements were performed by
segmenting images representing four TEM ﬁelds of view with
a total of n = 300−400 AuNP cores (IP Lab Spectrum, BD
Biosciences). The areas of cores were determined by calibrated
segmentation, average diameters were generated for each AuNP
core assuming circular symmetry, and the results presented as a
histogram. Cell culture samples were prepared as follows:
PANC-1 cells were treated with 0.1 mg/mL of AuNP3 in cell
culture medium and ﬁxed on the following day for 24 h with 1
M sodium cacodylate buﬀer (pH 7.4) containing 3%
glutaraldehyde and 2% formaldehyde. Samples were then
washed with 0.1% tannic acid/1 M sodium cacodylate and
treated with 1% osmium tetroxide. Finally, samples were
stained with 1% uranyl acetate, dehydrated with ethanol, and
embedded in LX-112 medium. After polymerization, samples
were cut on a microtome and double stained with uranyl
acetate/lead citrate. Imaging was done using a JEM1010
transmission electron microscope (Jeol USA, Inc. Boston, MA).
Animal Experiments. The animal protocol involving
99mTc-labeled, S-AcMAG3-NHS modiﬁed AuNP3 injections
was approved by the UMMS IACUC committee. To induce
local sterile inﬂammation, mice (DBA/2Ncr, n = 7/group)
were implanted with 0.1 mL of 50% Matrigel (Beckton-
Dickinson) containing 5 μg LPS from E. coli (Sigma-Aldrich, St.
Louis, MO) by injecting the ice-cold Matrigel solution using a
21 gauge needle syringe in the right femoral muscle 16 h before
the experiment. The left muscle was implanted with the same
volume of Matrigel containing no LPS.
The ectopic tumor model was obtained by implanting 1 ×
106 PANC-1 cells in the right ﬂank of female nu/nu mice (n =
8). Tumors reached the size of 0.5 cm in diameter in 3 weeks
after which animals were injected IV with 0.2 mL of 99mTc-
AuNP3 (600 μCi/animal) at a single dose of 0.2 mg Au/kg.
The biodistribution was performed at 22 h post injection.
For SPECT/CT imaging, the animals were anesthetized with
1.8% isoﬂurane/oxygen, and imaged 10 min, 4 h, 24 h, and 26 h
after the injection of 99mTc-AuNP3 (0.2 mg gold/kg) using
NanoSPECT/CT (Bioscan). Acquisition time was approx-
imately 30 min. The CT and SPECT reconstruction was
performed using InVivoScope 1.37 software (Bioscan) and
images were quantiﬁed using a volume-of-interest (VOI)
approach. Blood radioactivity over time in live animals was
quantiﬁed using the InVivoScope image postprocessing tool
after deﬁning the VOI. To select cylindrical VOI we ﬁrst
selected a circular region-of-interest from the transverse
projection image reconstruction and then selected the length
of the cylinder from the maximum intensity projection image.
Imaging at 26 h was used to determine inﬂammation/
background ratio and the blood pool radioactivity Fb =
k(VOIheart/VOItotal_body) × injected_dose, where k is the
radioactivity decay correction factor and VOI is the sum of
signals in the volume of interest.
For a biodistribution study in LPS-induced inﬂammation
model the animals were injected with two diﬀerent doses of
AuNP3:0.2 and 7.5 mg gold/kg (n = 7/group, radioactivity
dose 600−650 μCi 99mTc/animal). Blood sampling was
performed at various time points by nicking the tail vein, the
blood samples were weighed, and radioactivity in blood was
counted and normalized for weight and radioactivity decay. The
stability in plasma and urine was determined at 4 h post IV
injection by collecting the blood sample (0.1 mL) in
heparinized tubes, sedimenting the blood cells at 14 000 g
and determining the radioactivity in blood cells and plasma
separately. Plasma fractions were analyzed by HPLC on
Superose6 GL (1 × 30 cm) HPLC size-exclusion column
eluted with 20% acetonitrile in 0.1 M TrisHCl, pH 8.0 (0.6
mL/min). The animals were sacriﬁced after 22 h post I.V.
injection and the biodistribution of 99mTc-AuNP3 was
determined by using gamma-counting.
For ICP-MS (Galbraith Laboratories, Inc.) the major organs
of mice and muscle samples were weighed, frozen, and
lyophilized. Lyophilized samples were then dissolved in a mix
of HNO3:HCl (1:3 vol/vol).
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RF-Heating Experiments. The RF-induced heating
characteristics of solutions of AuNP3s at a concentration of
0.750 mg Au/mL were studied using the setup previously
described.25 Samples were placed in a 1.3 mL quartz cuvette
held by a custom-designed Teﬂon holder mounted to an
adjustable rotary stage under open air conditions at ambient
room temperature as described previously. The cuvette was
placed 0.8 cm from the transmission head of the RF-ﬁeld
generator located at an arbitrary point on the X−Y plane (7.6
cm, 10.2 cm) with an 8 cm air gap between transmitting and
receiving heads. The solutions were then exposed to the high
voltage RF ﬁelds (90 kV/m, as discussed below) at 950 W
generator power (13.56 MHz operating frequency). Temper-
atures were recorded every 0.1625 s with an infrared camera
(FLIR SC 6000, FLIR Systems, Inc., Boston, MA) for a
duration of 120 s or until the sample reached 70 °C (higher
temperatures were not attempted to prevent electrical arcing
due to excess water evaporation). The temperatures of four
control areas were also recorded to subtract any stray heating
eﬀects from the instrument and/or Teﬂon holder.
Permittivity Analysis. Complex permittivity measurements
were taken using an Agilent 85070E high-temperature coaxial
dielectric probe (Agilent Technologies, Santa Clara, CA)
connected to an Agilent E4991A impedance analyzer across
the frequency range 10 MHz to 1 GHz. Approximately 800
logarithmic data points were taken across the speciﬁed
frequency range with each measurement taken 10 times.
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